Antibody Drug Conjugates Global Market Report 2024

The antibody drug conjugates market size has grown exponentially in recent years. It will grow from $8.78 billion in 2023 to $10.7 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth observed during the historical period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the increasing prevalence of cancer, successful clinical outcomes leading to regulatory approvals, strategic collaborations between pharmaceutical companies, a rise in investment in research and development (R&D) initiatives, and the implementation of market expansion strategies.

The antibody drug conjugates market size is expected to see exponential growth in the next few years. It will grow to $24.8 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The anticipated growth in the forecast period in the antibody-drug conjugates (ADCs) market can be attributed to factors such as the development of next-generation ADCs, expanding indications for their use, an increasing focus on personalized medicine in cancer treatment, rising investment in precision medicine approaches, and a growing awareness of healthcare options. Major trends expected in the forecast period include advancements in conjugation technologies, an improved understanding of tumor biology influencing ADC development, ongoing technological advancements in the field, expanding therapeutic applications for ADCs, and the continuous evolution of advanced conjugation technologies for enhanced drug delivery.

The global antibody-drug conjugates market is witnessing significant growth driven by the increasing incidence of cancer worldwide. Primary causes of most cancers, including obesity, smoking, alcohol consumption, and poor dietary habits, contribute to a rising trend. Cancer Research UK projects a substantial increase, estimating 27.5 million new cancer cases annually by 2040. This surge in cancer incidences is expected to boost the demand for antibody-drug conjugates, thereby propelling market growth.

The upward trajectory of the antibody-drug conjugates market is further fueled by a growing number of clinical trial studies. Clinical trials, essential for testing new treatments and interventions, play a crucial role in disease management. Antibody-drug conjugates, as a significant category of anti-cancer medications, are undergoing numerous clinical trials for treating blood-related cancers and solid tumors. Notably, there has been a substantial increase in registered clinical trials worldwide, with 452,604 listed on ClinicalTrials.gov, as reported by The Xtalks in May 2023. This uptrend indicates the rising prominence of clinical studies, contributing to the expansion of the antibody-drug conjugates market.

Challenges in the manufacturing process of antibody-drug conjugates act as a restraint on market growth. ADC manufacturing facilities require substantial capital investment and specialized training for operators. The complexity of ADC process development, involving additional steps not present in conventional monoclonal antibody manufacturing, poses operational difficulties. Challenges include optimizing antibody-drug conjugation reactions and subsequent drug substance purification, along with the need for aseptic environments and protection of personnel from highly toxic drug compounds.

Manufacturers of antibody-drug conjugates are subject to monitoring by regulatory bodies, such as the Food and Drug Administration (FDA) in the USA. Although there is no specific regulatory guidance for ADC development, the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. Regulatory oversight focuses on aspects such as the manufacturing of the antibody component, control strategy for antibody intermediate, drug substance, and drug product. Small molecule review groups at the FDA play a key role in evaluating payload and linker adequacy, conjugation reactions, and aspects of the control strategy.

Manufacturers are increasingly engaging in collaborations and partnerships to share technology, resources, and product knowledge. An example is the collaboration between Sanofi, a French multinational pharmaceutical company, and Seagen Inc., a US biotechnology company, announced in March 2022. This collaboration aims to develop and market up to three cancer targets for antibody-drug conjugates, leveraging Sanofi's exclusive monoclonal antibody technology and Seagen's exclusive ADC technology. Such collaborations enhance synergies, fostering the creation of candidate medications to offer new hope to cancer patients.

Major companies in the antibody-drug conjugates market are introducing innovative breakthrough conjugates such as Ujvira to offer affordable new therapies. Ujvira, launched by Zydus Cadila in May 2021, is the world's first biosimilar antibody-drug conjugate of trastuzumab emtansine. This breakthrough treatment targets breast and stomach cancer by inhibiting the human epidermal growth factor receptor protein (HER2). Administered by qualified medical professionals, Ujvira represents a significant advancement in cancer therapy.

Major companies operating in the antibody drug conjugates market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Biogen Inc., Zydus Lifesciences Limited, Seagen Inc., Seagen Inc., Progenics Pharmaceuticals Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Fredax, Eisai Co. Ltd., Merck KGaA, Bracco S.p.A. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2023. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The main components of antibody-drug conjugates include monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are generated by cloning a single white blood cell, and each subsequent antibody is derived from a single parent cell. Some examples of ADC products include Adcetris, Kadcyla, and others. Various technologies, such as immunogen technology, Seattle Genetics technology, immunomedics technology, among others, are involved in the development of antibody-drug conjugates. These therapies find applications in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and others, and are implemented in hospitals, clinics, and other healthcare settings.

The antibody-drug conjugates (ADCs) market research report is one of a series of new reports that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The countries covered in the antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.